A first of its kind bispecific antibody, ivonescimab, combined with chemotherapy has shown promising early results in a phase 2 trial for patients with advanced triple negative breast cancer. The treatment targets both PD 1 and vascular endothelial growth factor, achieving encouraging objective response rates in previously untreated patients. Researchers now plan to advance the therapy to a larger phase 3 trial to confirm its efficacy and safety in this hard to treat cancer subtype.
What We Know
Triple negative breast cancer (TNBC) remains one of the most aggressive and difficult to treat forms of breast cancer, with limited therapeutic options for patients with advanced disease. A new phase 2 clinical trial, published in Nature Medicine, has evaluated ivonescimab, a bispecific antibody that simultaneously targets PD 1 and vascular endothelial growth factor (VEGF), in combination with chemotherapy. The trial included patients with treatment naive, locally advanced unresectable or metastatic TNBC.
The results demonstrated encouraging preliminary objective response rates, suggesting the combination therapy may offer a new treatment avenue for this patient population. The findings have prompted researchers to initiate plans for a larger, randomized phase 3 trial to further assess the therapy's potential.
Key Findings
The phase 2 trial enrolled patients who had not received prior systemic therapy for their advanced disease. Ivonescimab, developed to inhibit both PD 1 and VEGF pathways, was administered alongside standard chemotherapy. The dual mechanism of action aims to enhance anti tumor immunity while simultaneously cutting off the blood supply that tumors need to grow.
While the full data from the trial have not yet been disclosed, the reported objective response rates are considered promising, particularly given the historically poor prognosis for patients with advanced TNBC. The therapy was generally well tolerated, though detailed safety data will be critical as the trial progresses to the next phase.
Why This Matters
Triple negative breast cancer accounts for approximately 10 15% of all breast cancers but is responsible for a disproportionate share of breast cancer related deaths due to its aggressive nature and lack of targeted therapies. Current standard treatments, primarily chemotherapy, offer limited long term benefits for patients with advanced disease. The emergence of immunotherapies, such as PD 1 inhibitors, has provided new hope, but response rates remain modest, and many patients do not benefit from these treatments.
The development of bispecific antibodies like ivonescimab represents a novel approach to overcoming these challenges. By targeting both immune checkpoints and tumor angiogenesis, these therapies may enhance the body's ability to fight cancer while directly inhibiting tumor growth. If confirmed in larger trials, this combination could become a new standard of care for patients with advanced TNBC.
Expert Perspective
Dr. Lisa Carey, an oncologist and breast cancer specialist at the University of North Carolina Lineberger Comprehensive Cancer Center, who was not involved in the trial, noted the significance of the findings. "The early results with ivonescimab are encouraging, particularly for a disease where treatment options are so limited," she said. "The dual targeting of PD 1 and VEGF is a rational strategy, and if these results hold up in phase 3 trials, it could mark a meaningful advance for patients with triple negative breast cancer."
What's Next
The success of this phase 2 trial has set the stage for a phase 3 randomized controlled trial, which will compare ivonescimab plus chemotherapy against standard treatments. Researchers will closely monitor both efficacy and safety outcomes, with a focus on progression free survival, overall survival, and quality of life for patients. If the phase 3 trial confirms these early findings, ivonescimab could become one of the first bispecific antibodies approved for the treatment of triple negative breast cancer.
In the meantime, the medical community will be watching closely as more data emerge. For patients with advanced TNBC, these developments offer a glimmer of hope in an area where breakthroughs have been rare.
Key Takeaways
- A phase 2 trial of ivonescimab, a PD 1/VEGF bispecific antibody, combined with chemotherapy showed promising response rates in advanced triple negative breast cancer.
- The therapy targets both immune checkpoints and tumor blood supply, offering a novel approach for this hard to treat cancer subtype.
- A phase 3 trial is now planned to confirm these findings and assess the therapy's potential as a new standard of care.
Frequently Asked Questions
What is triple negative breast cancer?
Triple negative breast cancer is an aggressive form of breast cancer that lacks estrogen receptors, progesterone receptors, and HER2 protein. This makes it unresponsive to hormonal therapies and HER2 targeted treatments, leaving chemotherapy as the primary option.
How does ivonescimab work?
Ivonescimab is a bispecific antibody that simultaneously targets PD 1, an immune checkpoint protein, and VEGF, a protein that promotes blood vessel growth in tumors. This dual action aims to boost the immune response against cancer while starving tumors of their blood supply.
When might ivonescimab become available for patients?
Ivonescimab is still in the clinical trial phase. If the upcoming phase 3 trial confirms its efficacy and safety, it could take several years before regulatory approval and widespread availability.
Published by O. Ayodeji | Review by MedSense Editorial Board
DISCUSSION (0)
POST A COMMENT